Ex-CIA Advisor: “This is How Kamala will Rig the Election”

A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…

Click here now and learn how to prepare.

Sarah Rouan Biography and Net Worth

Director of Viking Therapeutics

Dr. Rouan has nearly 30 years of pharmaceutical industry experience and most recently served as senior vice president and head of Projects, Clinical Platforms and Sciences (PCPS) at GlaxoSmithKline (GSK). GSK’s PCPS encompasses the company’s global clinical operations, statistics and programming, clinical pharmacology, GCP quality, third party resourcing and project management functions and includes approximately 1,800 individuals in 20 countries. Dr. Rouan first joined GSK in 1989 with a background in pharmaceutical sciences, focusing on formulation development of protein pharmaceuticals. In 1993, she transitioned into project leadership and management becoming vice president and head of metabolism and pulmonary project management in 1999. In 2007, Dr. Rouan led the development, submission and approval of Arzerra® (ofatumumab) for refractory chronic lymphocytic leukemia. In 2012, she became head of biopharmaceutical development, assuming responsibility for delivery of GSK’s portfolio of biopharmaceutical medicines. In December 2013, Dr. Rouan was appointed senior vice president and head of research and development for Stiefel, GSK’s dermatology therapy area unit. Dr. Rouan earned a Ph.D. in pharmaceutical sciences from the University of Rhode Island and a B.Pharm. from the University of London.

What is Sarah Kathryn Rouan's net worth?: The estimated net worth of Sarah Kathryn Rouan is at least $560,953.00 as of May 17th, 2019. Dr. Rouan owns 8,350 shares of Viking Therapeutics stock worth more than $560,953 as of September 16th. This net worth approximation does not reflect any other assets that Dr. Rouan may own. Learn More about Sarah Kathryn Rouan's net worth.
How do I contact Sarah Kathryn Rouan?: The corporate mailing address for Dr. Rouan and other Viking Therapeutics executives is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. Viking Therapeutics can also be reached via phone at (858) 704-4660 and via email at [email protected]. Learn More on Sarah Kathryn Rouan's contact information.
Has Sarah Kathryn Rouan been buying or selling shares of Viking Therapeutics?: Sarah Kathryn Rouan has not been actively trading shares of Viking Therapeutics over the course of the past ninety days. Most recently, Sarah Kathryn Rouan sold 25,000 shares of the business's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $28.05, for a transaction totalling $701,250.00. Learn More on Sarah Kathryn Rouan's trading history.
Who are Viking Therapeutics' active insiders?: Viking Therapeutics' insider roster includes Matthew Foehr (Director), Brian Lian (CEO), Lawson Macartney (Director), Marianna Mancini (COO), Sarah Rouan (Director), Charles Rowland, Jr. (Director), J. Matthew Singleton (Director), Greg Zante (CFO), Greg Zante (CFO), and Greg Zante (CFO). Learn More on Viking Therapeutics' active insiders.
Are insiders buying or selling shares of Viking Therapeutics?: In the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 1,012,501 shares worth more than $54,639,024.05. The most recent insider tranaction occured on August, 21st when CEO Brian Lian sold 1,000 shares worth more than $69,900.00. Insiders at Viking Therapeutics own 4.7% of the company. Learn More about insider trades at Viking Therapeutics.
Information on this page was last updated on 8/21/2024.

Sarah Kathryn Rouan Insider Trading History at Viking Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/8/2024	Sell	25,000	$28.05	$701,250.00
1/19/2024	Sell	30,000	$23.05	$691,500.00

Sarah Kathryn Rouan Buying and Selling Activity at Viking Therapeutics

Viking Therapeutics Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $67.18

$64.54

$68.83

50 Day Range

MA: $58.00

$49.84

$66.73

2 Week Range

Now: $67.18

$8.28

$99.41

Volume

2,251,866 shs

Average Volume

4,548,935 shs

Market Capitalization

$7.44 billion

P/E Ratio

N/A

Dividend Yield